N@N

William Pickering Initiated (VRTX) at Buy and Held Target at $344 on, Mar 21st, 2023

William Pickering of Bernstein, Initiated "Vertex Pharmaceuticals Incorporated" (VRTX) at Buy and Held Target at $344 on, Mar 21st, 2023.

William has made no other calls on VRTX in the last 4 months.

There are 11 other peers that have a rating on VRTX. Out of the 11 peers that are also analyzing VRTX, 6 agree with William's Rating of Hold. Following are those relevant analyst calls for the last 4 months

---

• Paul Matteis of "Stifel" Maintained at Hold with Increased Target to $300 on, Thursday, February 9th, 2023
• Whitney Ijem of "Canaccord Genuity" Maintained at Hold with Increased Target to $312 on, Wednesday, February 8th, 2023
• Do Kim of "Piper Sandler" Maintained at Hold and Held Target at $296 on, Wednesday, February 8th, 2023
• Matthew Harrison of "Morgan Stanley" Maintained at Hold with Decreased Target to $285 on, Wednesday, February 8th, 2023
• Brian Abrahams of "RBC Capital" Maintained at Hold and Held Target at $303 on, Tuesday, February 7th, 2023
• Michael Yee of "Jefferies" Downgraded from Strong Buy to Hold and Held Target at $340 on, Monday, December 19th, 2022

These are the ratings of the 5 analyists that currently disagree with William

---

• Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $326 on, Wednesday, February 8th, 2023
• Colin Bristow of "UBS" Maintained at Strong Buy with Increased Target to $375 on, Wednesday, February 8th, 2023
• David Risinger of "SVB Leerink" Maintained at Buy with Decreased Target to $365 on, Wednesday, February 8th, 2023
• Evan Seigerman of "BMO Capital" Maintained at Buy and Held Target at $355 on, Wednesday, February 8th, 2023
• Gena Wang of "Barclays" Maintained at Buy with Increased Target to $342 on, Wednesday, February 8th, 2023

Contributing Sources

---